Abstract

Bone-derived factors that demonstrate extra-skeletal functions, also termed osteokines, are fast becoming a highly interesting and focused area of cross-disciplinary endocrine research. Osteocalcin (OCN), fibroblast growth factor-23 (FGF23) and lipocalin-2 (LCN-2), produced in bone, comprise an important endocrine system that is finely tuned with other organs to ensure homeostatic balance and health. This review aims to evaluate in vitro evidence of the direct involvement of these proteins in vascular cells and whether any causal roles in cardiovascular disease or inflammation can be supported. PubMed, Medline, Embase and Google Scholar were searched for relevant research articles investigating the exogenous addition of OCN, FGF23 or LCN-2 to vascular smooth muscle or endothelial cells. Overall, these osteokines are directly vasoactive across a range of human and animal vascular cells. Both OCN and FGF23 have anti-apoptotic properties and increase eNOS phosphorylation and nitric oxide production through Akt signalling in human endothelial cells. OCN improves intracellular insulin signalling and demonstrates protective effects against endoplasmic reticulum stress in murine and human endothelial cells. OCN may be involved in calcification but further research is warranted, while there is no evidence for a pro-calcific effect of FGF23 in vitro. FGF23 and LCN-2 increase proliferation in some cell types and increase and decrease reactive oxygen species generation, respectively. LCN-2 also has anti-apoptotic effects but may increase endoplasmic reticulum stress as well as have pro-inflammatory and pro-angiogenic properties in human vascular endothelial and smooth muscle cells. There is no strong evidence to support a pathological role of OCN or FGF23 in the vasculature based on these findings. In contrast, they may in fact support normal endothelial functioning, vascular homeostasis and vasodilation. No studies examined whether OCN or FGF23 may have a role in vascular inflammation. Limited studies with LCN-2 indicate a pro-inflammatory and possible pathological role in the vasculature but further mechanistic data is required. Overall, these osteokines pose intriguing functions which should be investigated comprehensively to assess their relevance to cardiovascular disease and health in humans.

Highlights

  • The role of the skeleton has greatly evolved from its premise of being a functional tissue providing primary protection, support, and haematopoietic maintenance

  • In order to assess the relevance of these osteokines to cardiovascular health, we aimed to provide an analysis of the direct effects of OCN, fibroblast growth factor-23 (FGF23) and LCN-2 on micro- and macro-vascular cells in vitro, and to highlight gaps in the literature which need addressing, for use by clinicians and researchers

  • To retrieve articles concerning the exogenous administration of OCN, FGF23 and LCN-2 to micro- or macro-vascular cells, the following search terms were used for database searching (PubMed, Embase, Medline, Google Scholar): fibroblast growth factor 23, bone gammacarboxyglutamic acid protein, osteocalcin, lipocalin 2, LCN-2, neutrophil gelatinaseassociated lipocalin, neutrophil gelatinase-associated lipocalin (NGAL), vascular cell, vascular endothelial cell, and vascular smooth muscle cell

Read more

Summary

Introduction

The role of the skeleton has greatly evolved from its premise of being a functional tissue providing primary protection, support, and haematopoietic maintenance. It is recognised as an endocrine organ providing exciting opportunities for cross-disciplinary research. The endothelial cells lining blood vessels have an important influence on bone cells, often in a paracrine manner, establishing a ‘bone-vascular axis’ (Brandi & Collin-Osdoby, 2006). This traditionally viewed axis is evolving to reflect that on the other hand, secreted, circulating bone-derived factors have direct effects on vascular cells themselves

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call